Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

39.44 -2.95 (-6.96%)
Streaming Delayed Price Updated: 1:28 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 949,805
Open 41.99
Bid (Size) 39.42 (200)
Ask (Size) 39.47 (100)
Prev. Close 42.39
Today's Range 39.39 - 43.20
52wk Range 9.570 - 43.69
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+100.7%
+100.7%
1 Month
+9.2%
+9.2%
3 Month
+139.5%
+139.5%
6 Month
+182.1%
+182.1%
1 Year
+96.6%
+96.6%

More News

Read More
Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals
Via Business Wire
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
Via Stocktwits
Earnings Scheduled For August 7, 2025
Via Benzinga
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Via Benzinga
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
Via The Motley Fool
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
Via Investor's Business Daily
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
Via Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Via Investor's Business Daily
Topics Death
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
Via Stocktwits
Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead (ARWR) Q3 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Arrowhead (ARWR) Q3 Revenue Drops 41%
Via The Motley Fool
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Mixed Q3 2025 Results with Revenue Beat but Wider-Than-Expected Loss
Via Chartmill
Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?
Via Benzinga
FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys
Via Benzinga
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 39.44
When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 11/03/25 01:28 PM ET
What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 4.17B
How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
Arrowhead Pharmaceuticals, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.